Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bafna PharmaceuticalsNSE:BAFNAPH +1.99%57 Shiller PE Ratio is 77.32 as of Sep. 08, 2026, which is 187% above its 10-year median of 26.94. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 57/100 and a GF Value™ of ₹85.76 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 527 Drug Manufacturers companies, Bafna Pharmaceuticals ranks worse than 88.8% on this metric.
The historical rank and industry rank for Bafna Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:
NSE:BAFNAPH'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.22 Med: 26.94 Max: 73.05
Current: 72.99
During the past years, Bafna Pharmaceuticals's highest Shiller PE Ratio was 73.05. The lowest was 18.22. And the median was 26.94.
NSE:BAFNAPH's Shiller PE Ratio is ranked worse than 88.8% of 527
companies
in the Drug Manufacturers industry
Industry Median: 25.54
vs NSE:BAFNAPH: 72.99
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Bafna Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was ₹0.030. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is ₹3.98 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Bafna Pharmaceuticals (NSE:BAFNAPH) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Bafna Pharmaceuticals Shiller PE Ratio Related Terms
Bafna Pharmaceuticals Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Bafna Pharmaceuticals's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's Shiller PE Ratio falls into.
Bafna Pharmaceuticals Shiller PE Ratio Calculation
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Shiller PE Ratio of 77.32 as of Sep. 08, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Bafna Pharmaceuticals and its competitors. This is 187% above median its historical median of 26.94. Over the past decade, Bafna Pharmaceuticals' Shiller PE Ratio has ranged from 18.22 to 73.05. According to the industry distribution chart, Bafna Pharmaceuticals ranks #468 out of 527 companies in the Drug Manufacturers industry, placing it in the top 88.8%.
Is Bafna Pharmaceuticals' Shiller PE Ratio too high?
Bafna Pharmaceuticals' current Shiller PE Ratio of 77.32 is 187% above median its 10-year median of 26.94. Over the past 10 years, this metric has ranged from a low of 18.22 to a high of 73.05. The Drug Manufacturers industry median Shiller PE Ratio is 25.54. Bafna Pharmaceuticals' value of 77.32 is 202.7% above this industry median. Based on the distribution chart, Bafna Pharmaceuticals ranks #468 out of 527 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bafna Pharmaceuticals has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Shiller PE Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #468 out of 527 companies for Shiller PE Ratio. This places Bafna Pharmaceuticals in the lower half of its industry. The industry median Shiller PE Ratio is 25.54. Bafna Pharmaceuticals' value of 77.32 is 202.7% above this benchmark. Historically, Bafna Pharmaceuticals' own Shiller PE Ratio has ranged from 18.22 to 73.05 over the past decade. While the company's 10-year median is 26.94 vs. the industry median of 25.54, Bafna Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 25.54, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bafna Pharmaceuticals's current Shiller PE Ratio of 77.32 is 202.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Bafna Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 25.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current Shiller PE Ratio is 77.32, which is 187% above median its own 10-year median of 26.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹85.76, compared to a current price of ₹307.75 — trading 258.9% above its estimated fair value. The current Shiller PE Ratio is 77.32, which is 187% above median its 10-year median of 26.94 and 202.7% above the Drug Manufacturers industry median of 25.54. Bafna Pharmaceuticals' overall GF Score™ is 57/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Shiller PE Ratio is 77.32 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹307.75 is trading 258.9% above its estimated GF Value™ of ₹85.76.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
Shiller PE Ratio: 77.32 (187% above median its 10-year median of 26.94)
GF Value™: ₹85.76 vs. price of ₹307.75 (258.9% above fair value)
Industry Position: 202.7% above the Drug Manufacturers median (#468 of 527)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
57GF Score
Get the complete analysis for NSE:BAFNAPH
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
